Medicare Part B Step Therapy Alpha1-Proteinase Inhibitors
Customize your policy alerts
Sign up for zing_health Policy 3445-D alerts
Get alerted when Policy 3445-D changes without checking for updates manually.
Monitor payer policy activity
This policy governs preferred-product sequencing and prior authorization exceptions for alpha1-proteinase inhibitor products under Medicare Part B. It affects members who are new to treatment with a non-preferred product and requires a clinical exception for non-preferred coverage.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.